RCAMU
ALXN

Rothschild & Co Asset Management US’s Alexion Pharmaceuticals ALXN Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,319
Closed -$647K – 567
2017
Q2 		$647K Buy
+5,319
New +$619K 0.01% 423

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rothschild & Co Asset Management US's ALXN Position: Q3 2017 in Review

Rothschild & Co Asset Management US sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 5,319 shares — an estimated $647K sold.

Rothschild & Co Asset Management US first reported a position in ALXN in Q2 2017 and held it in 1 quarter. The position peaked at $647K in Q2 2017. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Rothschild & Co Asset Management US reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 5,319 Alexion Pharmaceuticals shares in Q3 2017, an estimated $647K.
  • Rothschild & Co Asset Management US first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Rothschild & Co Asset Management US's Alexion Pharmaceuticals position peaked at $647K in Q2 2017.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2017, filed 8 Nov 2017.